ACE2 and COVID-19: It is still controversial as to whether patients receiving ACE inhibitors or angiotensin-receptor blockers could show enhanced susceptibility to SARS-CoV-2 infection or COVID-19 severity through increased ACE2 expression or attenuated inflammation and fibrosis, respectively.